Josh Thomas Georgy

Employment

• Christian Medical College & Hospital Asst Professor
  2025 - Present

Education

• Christian Medical College, Vellore DM
  2022 - 2025
• Christian Medical College & Hospital MD Internal Medicine
  2015 - 2018
• Christian Medical College & Hospital MBBS
  2007 - 2012
• University of Oxford
• Royal College of Physicians MRCP(UK)
  ? - 2024

Projects & Funding

Projects & funding information is unavailable.

Publications (44)

• Low-dose nivolumab with neoadjuvant chemotherapy and oral metronomic therapy in borderline resectable oral cavity squamous cell carcinoma: a phase II trial
  LANCET REGIONAL HEALTH - SOUTHEAST ASIA 2026 DOI: 10.1016/J.LANSEA.2026.100743
  +Save
• Neoadjuvant chemoimmunotherapy before chemoradiation vs chemoradiation alone for stage IIB-IIIC1 carcinoma of the cervix: A phase II open-label randomized controlled trial (NeoCHIMERA).
  JOURNAL OF CLINICAL ONCOLOGY 2026 DOI: 10.1200/JCO.2026.44.16_SUPPL.TPS5631
  +Save
• A two-step pre-treatment screening strategy combining enzyme phenotyping and targeted DPYD genotyping: A pragmatic approach for preventing fluoropyrimidine toxicity
  JOURNAL OF CLINICAL ONCOLOGY 2026 DOI: 10.1200/JCO.2026.44.19_SUPPL.306
  +Save
• Metastatic Malignant Pseudomyogenic Hemangioendothelioma: An Exceedingly Rare Entity That Challenges Conventional Paradigms
  International Journal of Surgical Pathology 2025 DOI: 10.1177/10668969241286068
  +Save
• Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non–Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score–Matched Analysis
  JCO Global Oncology 2025 DOI: 10.1200/GO-24-00256
  +Save
• Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer
  ECANCERMEDICALSCIENCE 2025 DOI: 10.3332/ECANCER.2025.1966
  +Save
• Therapeutic drug monitoring guided real world clinicopharmacological evaluation of thrice weekly osimertinib plus chemotherapy in EGFR-mutant advanced NSCLC: Phase II safety and efficacy study
  ANNALS OF ONCOLOGY 2025 DOI: 10.1016/J.ANNONC.2025.10.750
  +Save
• Comparative analysis of mutational patterns in triple negative breast cancer before and after neoadjuvant chemotherapy in patients with residual disease
  GENE 2024 DOI: 10.1016/J.GENE.2023.147980
  +Save
• Ultra-low dose nivolumab added to dose-dense, cisplatin-based neoadjuvant chemotherapy in locally advanced, borderline operable triple negative breast cancer: A matched case-control study
  CANCER RESEARCH 2024 DOI: 10.1158/1538-7445.SABCS23-PO5-03-11
  +Save
• Total Neoadjuvant Therapy (TNT) with Full Dose Concurrent Chemotherapy in Locally Advanced Rectal Adenocarcinoma Including Signet Ring and Mucinous Cancers
  JOURNAL OF GASTROINTESTINAL CANCER 2024 DOI: 10.1007/S12029-023-00941-4
  +Save